PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1 2, PALB2 or RAD51C D mutations from parp Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
Description: Dr Timothy Yap speaks to ecancer about the PETRA trial that he presented at the AACR 2022 meeting. The trial was a first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations.nnHe reports that the results showed that AZD5305 successfully improved safety and showed promising clinical activity.nnDr Yap believes that this is proof of concept in the clinic for this innovative strategy and that expansion trials ar